Wacker Biosolutions to focus on biotechnology

Published: 2-Mar-2010
Manufacturing Ingredients Finance Pharmaceutical

Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology

Wacker, the German chemical company, has changed the name of its Wacker Fine Chemicals division to Wacker Biosolutions as it gives the business a biotechnology focus.

Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.

The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.

Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.

"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.

Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.

See more

You may also like

Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Read more
Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan

Trending Articles

  1. Echo MS+ integration enhances high-throughput mass spectrometry SCIEX expands compatibility with the ZenoTOF 8600 system to deliver greater sensitivity and automation capabilities
  2. Drug-loaded pellets: unlocking flexible oral dosage design with modern pelletisation technologies Produced using advanced extrusion–spheronisation technologies such as GEA’s NICA systems, drug-loaded pellets are gaining traction as a flexible and scalable oral solid dosage platform that enhances release control, patient outcomes and manufacturing efficiency
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Automated visual inspection: reducing false rejects with intelligent bubble masking This article explores how intelligent bubble masking in automated visual inspection systems can significantly reduce false rejects in biopharmaceutical manufacturing by accurately distinguishing harmless bubbles from harmful particles
  4. Axol Bioscience expands ophthalmology portfolio with acquisition of Newcells Biotech business Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, strengthening its iPSC-derived retinal organoid and RPE model offerings
  5. CARBOGEN AMCIS and Celonic unveil integrated ADC development platform at World ADC London 2026 The strategic alliance combines biologics and highly potent payload capabilities to streamline ADC development and manufacturing

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Manufacturing

GEA opens new technology centre in Germany

The opening of the new technology centre for pharmaceutical freeze-drying systems will strengthen the supplier's position in the growing pharmaceutical applications market
Finance

Heligan Group report: UK healthcare M&A remains resilient

A new report from the investment group has highlighted the healthcare field as being a "defensive, structurally supported sector"
Manufacturing

Avoiding product degradation with a low-temperature, vacuum cake dryer

High-performance chemicals often lose efficacy when exposed to heat. Active pharmaceutical ingredients (APIs), fine chemical intermediates, and biologically derived materials are subject to product degradation and can transform, or lose potency under high drying temperatures. This thermal sensitivity demands precise control to maintain molecular stability and ensure product quality
Manufacturing

Cutting-edge customer projects - Specialised systems for multiple sectors

As specialists in laboratory and process chemistry equipment solutions, Labtex have expertise in designing, manufacturing, and installing customised systems for a diverse range industries and disciplines – including chemical manufacturing, drug development, and metals recovery
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Procurement as a strategic business enabler

How Alkermes unlocked $30m in project cost savings with JAGGAER
Manufacturing

AFYREN obtains FSSC 22000 certification for industrial site

The AFYREN NEOXY plant is now certified for the production and processing of biobased monocarboxylic acids and their derivatives for the food and feed industries, a guarantee of trust and performance for customers
Subscribe now